Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm adjuvant camrelizumab for MSI-H stage III gastric cancer after D2 gastrectomy
ChiCTR2100050575Phase 2Recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Changhai Hospital. Primary endpoint: 3-year disease-free survival. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100050575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050575.